Price Chart

Profile

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
URL https://www.anaptysbio.com
Investor Relations URL https://ir.anaptysbio.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 11, 2025 (est.)
Last Earnings Release Nov. 05, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A

Profile

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, our PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, our BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
URL https://www.anaptysbio.com
Investor Relations URL https://ir.anaptysbio.com/
HQ State/Province California
Sector Health Care
Industry Biotechnology
Equity Style Small Cap/Blend
Next Earnings Release Mar. 11, 2025 (est.)
Last Earnings Release Nov. 05, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date N/A